## First Regular Session Seventy-second General Assembly STATE OF COLORADO

### REENGROSSED

This Version Includes All Amendments Adopted in the House of Introduction

LLS NO. 19-0588.01 Kristen Forrestal x4217

**HOUSE BILL 19-1131** 

#### HOUSE SPONSORSHIP

**Jaquez Lewis,** Bird, Buentello, Caraveo, Cutter, Duran, Exum, Galindo, Gonzales-Gutierrez, Herod, Kennedy, McCluskie, McLachlan, Michaelson Jenet, Mullica, Roberts, Singer, Sirota, Snyder, Valdez A., Weissman

#### SENATE SPONSORSHIP

Winter,

#### **House Committees**

#### **Senate Committees**

Health & Insurance

101

102

# A BILL FOR AN ACT CONCERNING A REQUIREMENT TO SHARE THE WHOLESALE ACQUISITION COST OF A DRUG WHEN SHARING INFORMATION

103 CONCERNING THE DRUG WITH ANOTHER PARTY.

#### **Bill Summary**

(Note: This summary applies to this bill as introduced and does not reflect any amendments that may be subsequently adopted. If this bill passes third reading in the house of introduction, a bill summary that applies to the reengrossed version of this bill will be available at <a href="http://leg.colorado.gov">http://leg.colorado.gov</a>.)

The bill requires a drug manufacturer or wholesaler, or an agent or an employee of the manufacturer or wholesaler, to provide, in writing, the wholesale acquisition cost of a prescription drug to an entity or individual with whom the manufacturer, wholesaler, agent, or employee is sharing information concerning the drug.

HOUSE ord Reading Unamended March 4, 2019

HOUSE Amended 2nd Reading March 1, 2019

Shading denotes HOUSE amendment. <u>Double underlining denotes SENATE amendment.</u>

Capital letters or bold & italic numbers indicate new material to be added to existing statute.

Dashes through the words indicate deletions from existing statute.

The bill also requires the drug manufacturer or wholesaler, or an agent or employee of the manufacturer or wholesaler, to provide educational materials about the acquisition costs of other prescription drugs in the same therapeutic class.

1 Be it enacted by the General Assembly of the State of Colorado: 2 **SECTION 1.** In Colorado Revised Statutes, add 12-42.5-308 as 3 follows: 4 12-42.5-308. Manufacturer, agent, representative, employee 5 - drug cost information - required - definitions. (1) A MANUFACTURER, 6 OR A REPRESENTATIVE, AGENT, OR EMPLOYEE OF A MANUFACTURER, WHO 7 WHILE EMPLOYED BY OR UNDER CONTRACT TO REPRESENT A 8 MANUFACTURER ENGAGES IN PRESCRIPTION DRUG MARKETING, SHALL 9 PROVIDE TO A PRESCRIBER, IN WRITING, THE WHOLESALE ACQUISITION 10 COST OF A PRESCRIPTION DRUG WHEN, IN THE COURSE OF CONDUCTING 11 BUSINESS, THE MANUFACTURER, REPRESENTATIVE, AGENT, OR EMPLOYEE 12 PROVIDES INFORMATION CONCERNING THE DRUG TO THE PRESCRIBER. 13 (2) (a) WHEN PROVIDING THE INFORMATION REQUIRED BY 14 SUBSECTION (1) OF THIS SECTION, A MANUFACTURER, OR A 15 REPRESENTATIVE, AGENT, OR EMPLOYEE OF A MANUFACTURER, SHALL 16 ALSO DISSEMINATE THE NAMES AND WHOLESALE ACQUISITION COSTS OF 17 AT LEAST THREE GENERIC PRESCRIPTION DRUGS FROM THE SAME 18 THERAPEUTIC CLASS, OR IF THREE ARE NOT AVAILABLE, AS MANY AS ARE 19 AVAILABLE FOR PRESCRIPTIVE USE. 20 (b) FOR THE PURPOSES OF THIS SECTION: 21 (I) "PRESCRIBER" MEANS A HEALTH CARE PROVIDER LICENSED 22 PURSUANT TO THIS TITLE 12 WHO IS AUTHORIZED TO PRESCRIBE 23 CONTROLLED SUBSTANCES OR PRESCRIPTION DRUGS.

-2-

| 1  | (II) "PRESCRIPTION DRUG MARKETING" MEANS ANY ACTIVITY               |
|----|---|
| 2  | THAT MAY INCLUDE IN-PERSON MEETINGS, PHYSICAL MAILINGS,             |
| 3  | TELEPHONIC CONVERSATIONS, VIDEO CONFERENCING, ELECTRONIC            |
| 4  | MAILING OR TEXTING, OR FACSIMILE TRANSMISSIONS THAT PROVIDES        |
| 5  | EDUCATIONAL OR MARKETING INFORMATION OR MATERIALS REGARDING         |
| 6  | A PRESCRIPTION DRUG.  |
| 7  | (III) "THERAPEUTIC CLASS" MEANS A GROUP OF SIMILAR DRUGS            |
| 8  | THAT HAVE THE SAME OR SIMILAR MECHANISMS OF ACTION AND ARE USED     |
| 9  | TO TREAT A SPECIFIC CONDITION.                                      |
| 10 | SECTION 2. In Colorado Revised Statutes, add to article 280         |
| 11 | as relocated by House Bill 19-1172 12-280-308 as follows:           |
| 12 | 12-280-308. Manufacturer, agent, representative, employee -         |
| 13 | drug cost information - required - definitions. (1) A MANUFACTURER, |
| 14 | OR A REPRESENTATIVE, AGENT, OR EMPLOYEE OF A MANUFACTURER, WHO      |
| 15 | WHILE EMPLOYED BY OR UNDER CONTRACT TO REPRESENT A                  |
| 16 | MANUFACTURER ENGAGES IN PRESCRIPTION DRUG MARKETING, SHALL          |
| 17 | PROVIDE TO A PRESCRIBER, IN WRITING, THE WHOLESALE ACQUISITION      |
| 18 | COST OF A PRESCRIPTION DRUG WHEN, IN THE COURSE OF CONDUCTING       |
| 19 | BUSINESS, THE MANUFACTURER, REPRESENTATIVE, AGENT, OR EMPLOYEE      |
| 20 | PROVIDES INFORMATION CONCERNING THE DRUG TO THE PRESCRIBER.         |
| 21 | (2) (a) When providing the information required by                  |
| 22 | SUBSECTION (1) OF THIS SECTION, A MANUFACTURER, OR A                |
| 23 | REPRESENTATIVE, AGENT, OR EMPLOYEE OF A MANUFACTURER, SHALL         |
| 24 | ALSO DISSEMINATE THE NAMES AND WHOLESALE ACQUISITION COSTS OF       |
| 25 | AT LEAST THREE GENERIC PRESCRIPTION DRUGS FROM THE SAME             |
| 26 | THERAPEUTIC CLASS, OR IF THREE ARE NOT AVAILABLE, AS MANY AS ARE    |
| 27 | AVAILABLE FOR PRESCRIPTIVE USE.                                     |

-3-

| 1  | (b) FOR THE PURPOSES OF THIS SECTION:   |
|--|---|
| 2  | (I) "Prescriber" means a health care provider licensed  |
| 3  | PURSUANT TO THIS TITLE 12 WHO IS AUTHORIZED TO PRESCRIBE  |
| 4  | CONTROLLED SUBSTANCES OR PRESCRIPTION DRUGS.  |
| 5  | (II) "PRESCRIPTION DRUG MARKETING" MEANS ANY ACTIVITY   |
| 6  | THAT MAY INCLUDE IN-PERSON MEETINGS, PHYSICAL MAILINGS  |
| 7  | TELEPHONIC CONVERSATIONS, VIDEO CONFERENCING, ELECTRONIC  |
| 8  | MAILING OR TEXTING, OR FACSIMILE TRANSMISSIONS THAT PROVIDES  |
| 9  | EDUCATIONAL OR MARKETING INFORMATION OR MATERIALS REGARDING   |
| 10   | A PRESCRIPTION DRUG.  |
| 11   | (III) "THERAPEUTIC CLASS" MEANS A GROUP OF SIMILAR DRUGS  |
| 12   | THAT HAVE THE SAME OR SIMILAR MECHANISMS OF ACTION AND ARE USED   |
| 13   | TO TREAT A SPECIFIC CONDITION.  |
|  |   |
| 14   | SECTION 3. Act subject to petition - effective date. (1) Except   |
| 14<br>15   | <b>SECTION 3.</b> Act subject to petition - effective date. (1) Except as otherwise provided in subsection (2) of this section, this act takes  |
|  | •   |
| 15   | as otherwise provided in subsection (2) of this section, this act takes   |
| 15<br>16   | as otherwise provided in subsection (2) of this section, this act takes effect at 12:01 a.m. on the day following the expiration of the ninety-day  |
| 15<br>16<br>17                                     | as otherwise provided in subsection (2) of this section, this act takes effect at 12:01 a.m. on the day following the expiration of the ninety-day period after final adjournment of the general assembly (August 2, 2019)  |
| 15<br>16<br>17<br>18                               | as otherwise provided in subsection (2) of this section, this act takes effect at 12:01 a.m. on the day following the expiration of the ninety-day period after final adjournment of the general assembly (August 2, 2019 if adjournment sine die is on May 3, 2019); except that, if a referendum  |
| 15<br>16<br>17<br>18<br>19                         | as otherwise provided in subsection (2) of this section, this act takes effect at 12:01 a.m. on the day following the expiration of the ninety-day period after final adjournment of the general assembly (August 2, 2019 if adjournment sine die is on May 3, 2019); except that, if a referendum petition is filed pursuant to section 1 (3) of article V of the state  |
| 15<br>16<br>17<br>18<br>19<br>20                   | as otherwise provided in subsection (2) of this section, this act takes effect at 12:01 a.m. on the day following the expiration of the ninety-day period after final adjournment of the general assembly (August 2, 2019 if adjournment sine die is on May 3, 2019); except that, if a referendum petition is filed pursuant to section 1 (3) of article V of the state constitution against this act or an item, section, or part of this act within  |
| 15<br>16<br>17<br>18<br>19<br>20<br>21             | as otherwise provided in subsection (2) of this section, this act takes effect at 12:01 a.m. on the day following the expiration of the ninety-day period after final adjournment of the general assembly (August 2, 2019 if adjournment sine die is on May 3, 2019); except that, if a referendum petition is filed pursuant to section 1 (3) of article V of the state constitution against this act or an item, section, or part of this act within such period, then the act, item, section, or part will not take effect unless  |
| 15<br>16<br>17<br>18<br>19<br>20<br>21<br>22       | as otherwise provided in subsection (2) of this section, this act takes effect at 12:01 a.m. on the day following the expiration of the ninety-day period after final adjournment of the general assembly (August 2, 2019 if adjournment sine die is on May 3, 2019); except that, if a referendum petition is filed pursuant to section 1 (3) of article V of the state constitution against this act or an item, section, or part of this act within such period, then the act, item, section, or part will not take effect unless approved by the people at the general election to be held in November  |
| 15<br>16<br>17<br>18<br>19<br>20<br>21<br>22<br>23 | as otherwise provided in subsection (2) of this section, this act takes effect at 12:01 a.m. on the day following the expiration of the ninety-day period after final adjournment of the general assembly (August 2, 2019 if adjournment sine die is on May 3, 2019); except that, if a referendum petition is filed pursuant to section 1 (3) of article V of the state constitution against this act or an item, section, or part of this act within such period, then the act, item, section, or part will not take effect unless approved by the people at the general election to be held in November 2020 and, in such case, will take effect on the date of the official |

-4- 1131